Literature DB >> 8477416

Induction of cell-mediated immunity against B16-BL6 melanoma in mice vaccinated with cells modified by hydrostatic pressure and chemical crosslinking.

A Eisenthal1, V Ramakrishna, Y Skornick, M Shinitzky.   

Abstract

In the preceding paper we have demonstrated an increase in presentation of both major histocompatibility complex antigens (MHC) and a tumor-associated antigen of the weakly immunogenic B16 melanoma by a straight-forward technique. The method consists in modulating the tumor cell membrane by hydrostatic pressure and simultaneous chemical crosslinking of the cell-surface proteins. In B16-BL6 melanoma, the induced antigenic modulation was found to persist for over 48 h, which permitted the evaluation of the ability of modified B16-BL6 cells to induce immunity against unmodified B16-BL6 cells. In the present study, we have shown that a significant systemic immunity was induced only in mice that were immunized with modified B16-BL6 melanoma cells, whereas immunization with unmodified B16-BL6 cells had only a marginal effect when compared to the results in control sham-immunized mice. The induced immunity was specific since a single immunization affected the growth of B16-BL6 tumors but had no effect on MCA 106, an antigenically unrelated tumor. The addition of interleukin-2 to the immunization regimen had no effect on the antitumor responses induced by the modified B16-BL6 cells. The cell-mediated immunity conferred by immunization with treated B16-BL6 cells was confirmed in experiments in vitro where splenocytes from immunized mice could be sensitized to proliferate by the presence of B16-BL6 cells. In addition, the altered antigenicity of these melanoma cells appeared to correlate with their increased susceptibility to specific effectors. Thus, 51Cr-labeled B16-BL6 target cells, modified by pressure and crosslinking, in comparison to control labeled target cells, were lysed in much greater numbers by effectors such as lymphokine-activated killer cells and allogeneic cytotoxic lymphocytes (anti-H-2b), while such cells remained resistant to lysis by natural killer cells. Our findings indicate that the physical and chemical modifications of the tumor cells that are described here may be considered as a simple yet effective method for the preparation of tumor vaccines, which could be applied in tumor-bearing hosts.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8477416     DOI: 10.1007/bf01741168

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  27 in total

1.  Macrophages isolated from regressing Moloney sarcomas are more cytotoxic than those recovered from progressing sarcomas.

Authors:  S W Russell; A T McIntosh
Journal:  Nature       Date:  1977-07-07       Impact factor: 49.962

Review 2.  Immunotherapy of cancer using interleukin 2: current status and future prospects.

Authors:  S A Rosenberg
Journal:  Immunol Today       Date:  1988-02

3.  The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens.

Authors:  P J Bjorkman; M A Saper; B Samraoui; W S Bennett; J L Strominger; D C Wiley
Journal:  Nature       Date:  1987 Oct 8-14       Impact factor: 49.962

4.  The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens.

Authors:  T L Darrow; C L Slingluff; H F Seigler
Journal:  J Immunol       Date:  1989-05-01       Impact factor: 5.422

5.  Potentiation of delayed-type hypersensitivity response to syngeneic tumors in mice prevaccinated with cells modified by hydrostatic pressure and crosslinking.

Authors:  V Ramakrishna; M Shinitzky
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

Review 6.  Natural killer cells.

Authors:  R B Herberman
Journal:  Annu Rev Med       Date:  1986       Impact factor: 13.739

7.  Increased projection of MHC and tumor antigens in murine B16-BL6 melanoma induced by hydrostatic pressure and chemical crosslinking.

Authors:  V Ramakrishna; A Eisenthal; Y Skornick; M Shinitzky
Journal:  Cancer Immunol Immunother       Date:  1993-05       Impact factor: 6.968

8.  In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2.

Authors:  P J Spiess; J C Yang; S A Rosenberg
Journal:  J Natl Cancer Inst       Date:  1987-11       Impact factor: 13.506

9.  The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity.

Authors:  H Fujiwara; M Fukuzawa; T Yoshioka; H Nakajima; T Hamaoka
Journal:  J Immunol       Date:  1984-09       Impact factor: 5.422

10.  Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor.

Authors:  K Itoh; C D Platsoucas; C M Balch
Journal:  J Exp Med       Date:  1988-10-01       Impact factor: 14.307

View more
  3 in total

Review 1.  Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy.

Authors:  Irena Adkins; Jitka Fucikova; Abhishek D Garg; Patrizia Agostinis; Radek Špíšek
Journal:  Oncoimmunology       Date:  2015-01-07       Impact factor: 8.110

Review 2.  Current Approaches for Combination Therapy of Cancer: The Role of Immunogenic Cell Death.

Authors:  Zahra Asadzadeh; Elham Safarzadeh; Sahar Safaei; Ali Baradaran; Ali Mohammadi; Khalil Hajiasgharzadeh; Afshin Derakhshani; Antonella Argentiero; Nicola Silvestris; Behzad Baradaran
Journal:  Cancers (Basel)       Date:  2020-04-23       Impact factor: 6.639

Review 3.  Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines.

Authors:  Lien Vandenberk; Jochen Belmans; Matthias Van Woensel; Matteo Riva; Stefaan W Van Gool
Journal:  Front Immunol       Date:  2016-01-14       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.